GALECTIN THERAPEUTICS INC — Director's Dealing 2020

Jan 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-01-09

Reporting Person: LEWIS JOEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-09	Common Stock	A	20455	$2.86	Acquired	99104	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-09	Stock option (right to buy)	$2.86	A	40000	Acquired	2030-01-09	Common Stock (40000)	Direct

Footnotes

F1: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $58,500 for 2020. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2020.

F2: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan

F3: The options vest 100% on December 31, 2020.